 Melissa Wilson
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 15 | 2026 | 3195 | 1.190 |
Why?
| | Exercise Therapy | 4 | 2026 | 475 | 0.920 |
Why?
| | Exercise | 8 | 2026 | 2205 | 0.890 |
Why?
| | Healthy Aging | 2 | 2024 | 44 | 0.870 |
Why?
| | Patient Dropouts | 1 | 2025 | 66 | 0.870 |
Why?
| | Self Efficacy | 1 | 2024 | 413 | 0.660 |
Why?
| | Aging | 4 | 2024 | 1973 | 0.520 |
Why?
| | Health Personnel | 1 | 2022 | 757 | 0.460 |
Why?
| | Stress, Psychological | 1 | 2022 | 1149 | 0.400 |
Why?
| | Melanoma | 4 | 2023 | 761 | 0.390 |
Why?
| | Body Composition | 3 | 2026 | 693 | 0.330 |
Why?
| | Frailty | 2 | 2023 | 205 | 0.300 |
Why?
| | Absorptiometry, Photon | 2 | 2026 | 277 | 0.260 |
Why?
| | Macaca mulatta | 2 | 2024 | 186 | 0.240 |
Why?
| | Chimerism | 1 | 2025 | 35 | 0.230 |
Why?
| | High-Intensity Interval Training | 1 | 2026 | 45 | 0.230 |
Why?
| | Pyridones | 2 | 2024 | 209 | 0.220 |
Why?
| | Bias | 1 | 2025 | 197 | 0.210 |
Why?
| | Humans | 34 | 2026 | 145763 | 0.200 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 368 | 0.200 |
Why?
| | Chromosomes, Human, Y | 1 | 2023 | 37 | 0.200 |
Why?
| | Alanine | 1 | 2024 | 169 | 0.190 |
Why?
| | Genetic Variation | 2 | 2025 | 976 | 0.190 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 57 | 0.180 |
Why?
| | Activities of Daily Living | 2 | 2023 | 444 | 0.180 |
Why?
| | Osteoporosis | 1 | 2025 | 239 | 0.180 |
Why?
| | Tenofovir | 1 | 2024 | 301 | 0.180 |
Why?
| | Morals | 1 | 2022 | 79 | 0.170 |
Why?
| | Bone Density | 1 | 2025 | 487 | 0.170 |
Why?
| | Aged | 11 | 2026 | 26215 | 0.170 |
Why?
| | Longitudinal Studies | 2 | 2026 | 2967 | 0.170 |
Why?
| | Computer Simulation | 1 | 2025 | 1003 | 0.160 |
Why?
| | Kidney Diseases | 1 | 2025 | 426 | 0.160 |
Why?
| | Guideline Adherence | 1 | 2025 | 587 | 0.160 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 102 | 0.160 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2021 | 88 | 0.160 |
Why?
| | Transcriptome | 2 | 2024 | 1042 | 0.160 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6085 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 143 | 0.160 |
Why?
| | Sequence Analysis, DNA | 1 | 2023 | 778 | 0.160 |
Why?
| | Heart Rate | 1 | 2024 | 856 | 0.160 |
Why?
| | Heterografts | 2 | 2017 | 143 | 0.160 |
Why?
| | Education, Distance | 1 | 2021 | 59 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 561 | 0.160 |
Why?
| | Social Stigma | 1 | 2022 | 173 | 0.150 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 120 | 0.150 |
Why?
| | Occupational Therapy | 1 | 2022 | 109 | 0.150 |
Why?
| | Sarcopenia | 1 | 2021 | 91 | 0.150 |
Why?
| | Phenotype | 2 | 2026 | 3170 | 0.150 |
Why?
| | Interleukin-10 | 1 | 2021 | 310 | 0.150 |
Why?
| | Middle Aged | 11 | 2026 | 36302 | 0.140 |
Why?
| | Research Design | 1 | 2025 | 1139 | 0.140 |
Why?
| | Sex Characteristics | 1 | 2024 | 789 | 0.140 |
Why?
| | Rho Guanine Nucleotide Exchange Factors | 1 | 2018 | 27 | 0.140 |
Why?
| | Genomics | 1 | 2023 | 830 | 0.130 |
Why?
| | Algorithms | 1 | 2026 | 1850 | 0.130 |
Why?
| | Male | 15 | 2026 | 73003 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2026 | 1202 | 0.130 |
Why?
| | Female | 16 | 2026 | 79035 | 0.130 |
Why?
| | Kidney | 1 | 2025 | 1496 | 0.120 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 364 | 0.120 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 314 | 0.120 |
Why?
| | Mass Screening | 1 | 2025 | 1361 | 0.120 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1430 | 0.120 |
Why?
| | Pre-Eclampsia | 1 | 2018 | 206 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2181 | 0.110 |
Why?
| | Genome | 1 | 2017 | 305 | 0.110 |
Why?
| | Muscle, Skeletal | 2 | 2023 | 1791 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 936 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3416 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2022 | 1197 | 0.100 |
Why?
| | Microbiota | 1 | 2021 | 730 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 768 | 0.090 |
Why?
| | Inflammation | 2 | 2021 | 2883 | 0.090 |
Why?
| | Telemedicine | 1 | 2022 | 966 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2969 | 0.090 |
Why?
| | DNA | 1 | 2018 | 1437 | 0.090 |
Why?
| | Blood Pressure | 1 | 2018 | 1782 | 0.080 |
Why?
| | Quality of Life | 2 | 2022 | 3210 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2025 | 17325 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2399 | 0.070 |
Why?
| | Genotype | 2 | 2025 | 1857 | 0.060 |
Why?
| | Adult | 7 | 2024 | 40872 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8346 | 0.050 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 58 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.050 |
Why?
| | Deleted in Azoospermia 1 Protein | 1 | 2023 | 4 | 0.050 |
Why?
| | Segmental Duplications, Genomic | 1 | 2023 | 8 | 0.050 |
Why?
| | Tandem Repeat Sequences | 1 | 2023 | 23 | 0.050 |
Why?
| | DNA, Satellite | 1 | 2023 | 18 | 0.050 |
Why?
| | Pandemics | 2 | 2023 | 1711 | 0.050 |
Why?
| | Resistance Training | 1 | 2026 | 186 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 79 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2023 | 15 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2023 | 19 | 0.050 |
Why?
| | Reference Standards | 1 | 2023 | 177 | 0.050 |
Why?
| | Heterochromatin | 1 | 2023 | 66 | 0.050 |
Why?
| | Multigene Family | 1 | 2023 | 210 | 0.050 |
Why?
| | Solitary Nucleus | 1 | 2022 | 25 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 191 | 0.050 |
Why?
| | Los Angeles | 1 | 2022 | 73 | 0.050 |
Why?
| | Animals | 5 | 2025 | 38097 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2023 | 125 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2025 | 318 | 0.050 |
Why?
| | Genetics, Population | 1 | 2023 | 217 | 0.040 |
Why?
| | Viral Load | 1 | 2024 | 526 | 0.040 |
Why?
| | Alleles | 1 | 2025 | 896 | 0.040 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 15 | 0.040 |
Why?
| | Adenine | 1 | 2024 | 339 | 0.040 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 39 | 0.040 |
Why?
| | Taxoids | 1 | 2021 | 114 | 0.040 |
Why?
| | Psoas Muscles | 1 | 2021 | 14 | 0.040 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 57 | 0.040 |
Why?
| | Hospitalization | 2 | 2022 | 2460 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 80 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 6032 | 0.040 |
Why?
| | Social Environment | 1 | 2022 | 252 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2024 | 494 | 0.040 |
Why?
| | Telomere | 1 | 2023 | 287 | 0.040 |
Why?
| | Base Sequence | 1 | 2023 | 2171 | 0.040 |
Why?
| | Actigraphy | 1 | 2020 | 148 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2023 | 447 | 0.040 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 308 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2023 | 630 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 8075 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 693 | 0.040 |
Why?
| | DNA Methylation | 1 | 2023 | 690 | 0.030 |
Why?
| | Patient Compliance | 1 | 2022 | 588 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2023 | 740 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 534 | 0.030 |
Why?
| | HIV-1 | 1 | 2024 | 908 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2017 | 117 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 553 | 0.030 |
Why?
| | Europe | 1 | 2018 | 421 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 560 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 735 | 0.030 |
Why?
| | Oncogenes | 1 | 2017 | 118 | 0.030 |
Why?
| | Fatigue | 1 | 2019 | 365 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 779 | 0.030 |
Why?
| | Anti-HIV Agents | 1 | 2024 | 912 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1217 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 308 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2601 | 0.030 |
Why?
| | Machine Learning | 1 | 2021 | 587 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1083 | 0.030 |
Why?
| | Students | 1 | 2021 | 652 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 796 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 859 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5922 | 0.020 |
Why?
| | Prognosis | 1 | 2021 | 4329 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1969 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2933 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 2770 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3634 | 0.020 |
Why?
| | Mice | 2 | 2017 | 18355 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4151 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 3551 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4302 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1557 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2977 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 4090 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7215 | 0.010 |
Why?
| | United States | 1 | 2018 | 16123 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|